Autoimmune Diseases Working Party

Raffaella Greco, ADWP Chair
Tobias Alexander, ADWP Secretary
Manuela Badoglio, ADWP Study Coordinator

Number of HSCT for Autoimmune Diseases: 3514
EBMT Registry – February 2021

Principle research studies
1- MS Comparison of CYC+ATG vs. BEAM+ATG conditioning regimens in autologous HSCT for MS
2- NISSC II: Post-AHSCT management and mechanistic immunological reconstitution for patients with systemic sclerosis
3- Late complications after autologous HSCT for Autoimmune Diseases
4- Viral reactivations: retrospective study on viral infections post auto-HSCT in Autoimmune Diseases
5- Indications and outcomes of re-transplantation for Autoimmune Diseases
6- Prospective non-interventional on patients with multiple sclerosis (OMSET).

Disease-specific retrospective studies of autologous HSCT
- Immune cytopensias
- Rare neurological diseases (CIDP, Stiff Person Syndrome, myasthenia gravis, NMO and others, ADWP)
- Behçet’s Disease
- Juvenile and adult systemic arthritis/Still’s disease
- Polymyositis/Dermatomyositis

Surveys
- Survey of national provision/reimbursement of HSCT and follow up in Autoimmune Diseases
- HSCT in adult rheumatological autoimmun e diseases : guidelines and recommendations from the EBMT ADWP in collaboration with European Reference Network (ERN) for rare and complex connective tissue diseases (ERN ReCONNECT)
- Position paper with European Academy of Neurology EAN/ECTRIMS and EBMT: Prospective long-term follow of studies involving EBMT registry
  a- Harmonisation of long-term follow-up of clinical trials in MS (EBMT involvement TBC)

Key publications
- Rehabilitation before and after Autologous HSCT for patients with Multiple Sclerosis : Consensus guidelines and recommendations for best clinical practice on behalf of the ADWP, Nurses Group and Patient Advocacy Committee of the EBMT. Roberts F et al. Frontiers in Neurology. 2020, 11 December 2020
- Diagnosis and Management of Secondary HLH/MA S Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the ADWP and TCWP. Sanders RD, et al. Front Immunol. 2020 Mar 31;11:524
- Evaluating the clinical effectiveness of autologous HSCT versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the ADWP EBMT. Tappeden P et al. (2020). Bone Marrow Transplant. 55(7):1473-1475
- Autologous HSCT with reduced-intensity conditioning regimens in refractory Takayasu arteritis: a retrospective multicenter case-series from the EBMT of the EBMT. Laurent C et al. (2020). Bone Marrow Transplant. Apr 22
- Autimmune cytopensias (AIC) following allogeneic HSCT for acquired aplastic anemia: a joint study of the ADWP/SAAWP of the EBMT. Miller, P.D.E et al. (2020). Bone Marrow Transplant. 55, 441-451
- Autologous HSCT for ANCA-associated vasculitis: a retrospective survey of patients reported to EBMT registry. Alexander, T et al. (2020). Bone Marrow Transplant. 55(7):1512-1515